The Global Neuroleptic market is estimated to grow at a significant CAGR during the forecast period. Antipsychotic drugs, often known as major sedatives or neuroleptics, are used to treat psychosis. Schizophrenia, hallucinations, delusions, bipolar disorder, and other psychotic conditions are among the most prevalent for which these drugs are prescribed. Because of the growing number of Schizophrenic patients, the market for antipsychotic drugs is expected to grow. According to the American Psychiatric Association (APA), around one out of every twenty-four patients in 2018 had severe mental illnesses, including major psychotic disorders.
A full report of Neuroleptic Market is available at: https://www.omrglobal.com/industry-reports/neuroleptic-market
The rising incidence of psychiatric disorders places a significant pressure on healthcare system. As a result, the government is focused on raising awareness about disorders and the efficacy of drugs used to treat them. As a result, there is a huge demand for highly effective and safe drugs to treat people with psychotic disorders all over the globe. Furthermore, the firms are concentrating on the identification of innovative antipsychotic injectable drugs that reduce the need to monitor the patient’s drug consumption. Schizophrenia and psychotic disorders have a high incidence, which is driving the global antipsychotic drug market. Additional reasons driving the market growth for antipsychotic drugs include increased drug abuse, over-prescription of drugs, and addiction to antipsychotic drugs.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/neuroleptic-market
In March 2020, Dr. Reddy’s Laboratories announced the launch of Ziprasidone Mesylate for injection, 20 mg (base)/ml single-dose vials, in the United States. Ziprasidone Mesylate for injection is the generic therapeutic equivalent to Pfizer’s Geodon injection.
In January 2020, The US Food and Medication Administration (FDA) had approved Alkermes’ experimental antipsychotic drug candidate ALKS 3831 (olanzapine/samidorphan), which is used to treat schizophrenia and bipolar I disorder.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment covered
o By Type
o By Application
o By distribution
- Competitive Landscape- Eli Lily and Company., AstraZeneca., GlaxoSmithKline plc., Johnson & Johnson., Otsuka Pharmaceutical Co, Ltd., and Pfizer Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Market Segmentation
By Type
- Risperidone
- Olanzapine
- Quetiapine
- Ziprasidone
- Aripiprazole
- Paliperidone
- Lurasidone
By Application
- Bipolar I Disorder
- Schizophrenia
- Schizoaffective Disorder
- Major Depressive Disorder (MDD)
By Distribution
- Hospital Pharmacy
- Retail Pharmacy
- Drug Store
- E-commerce
Company Profiles
- Eli Lily and Company.
- AstraZeneca.
- GlaxoSmithKline plc.
- Johnson & Johnson.
- Otsuka Pharmaceutical Co, Ltd.
- Pfizer Inc.
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
